舒尼替尼二线治疗晚期胃肠间质瘤的单中心报告  

Sunitinib as second-line therapy for advanced gastrointestinal stromal tumors:experience from a single center

作　　者：孙永琨[1] 杨林[1] 依荷芭丽·迟[1] 张雯[1] 王金万[1] 孙燕[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院内科,北京100021

出　　处：《临床肿瘤学杂志》2013年第9期808-811,共4页Chinese Clinical Oncology

摘　　要：目的初步观察苹果酸舒尼替尼二线治疗晚期胃肠间质瘤(GIST)的疗效及不良反应。方法 2009年3月至2009年10月共入组7例患者,口服舒尼替尼单药,50mg/天,服用4周,6周为1周期。结果 7例患者中有1例治疗1周期后退出试验,其余6例患者中位治疗7个周期(2～22个周期);最佳疗效均为SD;中位无进展生存期为9个月(2.5～29.5个月),中位总生存期为28个月(4～49个月)。7例患者均出现不良反应,主要为1～2级,常见的不良反应包括白细胞减少、血小板减少、腹泻、镜下血尿、乏力、蛋白尿,另有1例患者出现心力衰竭。结论苹果酸舒尼替尼二线治疗晚期GIST有效,不良反应可以耐受。Objective To observe the efficacy and safety profile of malate sunitinib as second-line therapy for patients with advanced gastrointestinal stromal tumors （GISTs）. Methods From March 2009 to October 2009, 7 patients with advanced GISTs were enrolled. They were treated with sunitinib 50mg daily for 4 weeks with 2-week interval, and 6 weeks was a cycle. Results One of the 7 patients withdrew from the study after 1 cycle treatment, and the median treatment duration of the other 6 patients was 7 cycles （2-22 cycles） , the best response were all SD, the median progression-free survival was 9.0 months （2. 5-29. 5 months） , and the medi- an overall survival was 28 months（4-49 months）. All the patients experienced adverse events, mainly in grade 1-2. The common e- vents included leukopenia, thrombocytopenia, diarrhea, microscopic hematuria, fatigue, and proteinuria. One patient experienced heart failure. Conclusion Malate sunitinib was effective and well-tolerated for advanced GISTs as second-line treatment.

关 键 词：舒尼替尼 胃肠道间质瘤 二线治疗 

分 类 号：R735.2[医药卫生—肿瘤] R735.3[医药卫生—临床医学]